ArticleGene therapy2000
Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 58 citations in OpenAlex.
- Specificity of oligonucleotide gene therapy (OGT) agents.Theranostics · 2022Review
- Use of Nanoparticles in Delivery of Nucleic Acids for Melanoma Treatment.Methods in molecular biology (Clifton, N.J.) · 2021Article
- pcDNA3.1(-)-mediated ribozyme targeting of HER-2 suppresses breast cancer tumor growth.Molecular biology reports · 2010Article
- New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids.Acta naturae · 2009Article
- Therapeutic regulation of gene expression in the inner ear using RNA interference.Advances in oto-rhino-laryngology · 2009Review
- Gene therapy for carcinoma of the breast.Cancer gene therapy · 2006Review
- Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.Cancer gene therapy · 2006Article
- Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo.Journal of biomedicine & biotechnology · 2006Article
- Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.Molecular and cellular biology · 2005Article
- Bcl2-low-expressing MCF7 cells undergo necrosis rather than apoptosis upon staurosporine treatment.The Biochemical journal · 2004Article
- Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth.Gene therapy · 2002Article
- C-SPACE (cleavage-specific amplification of cDNA ends): a novel method of ribozyme-mediated gene identification.Nucleic acids research · 2001Article
- A selection system for identifying accessible sites in target RNAs.RNA (New York, N.Y.) · 2001Article
- Ets regulation of the erbB2 promoter.Oncogene · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
HER-2/neu is overexpressed in 25-30% of human breast cancers. We prepared an anti-HER-2/neu hammerhead ribozyme expressed by a recombinant adenovirus (rAdHER-Rz). Human breast cancer cell lines were transduced with high efficiency, resulting in decreased HER-2/neu expression. In vivo injections of rAdHER-Rz into BT-474 tumors established in nude mice inhibited tumor growth to 20% of mock-treated controls. Similar in vivo effects were shown in MCF-7 cells, which do not overexpress HER-2/neu. The growth inhibitory effects of rAdHER-Rz were greater than those of an antisense-expressing vector. These results suggest the utility of anti-HER-2/neu ribozymes as a rational strategy for gene therapy of breast cancer. Gene Therapy (2000) 7, 241-248.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.